— Know what they know.
Not Investment Advice

KNSA NASDAQ

Kiniksa Pharmaceuticals International, plc
1W: -8.2% 1M: -2.8% 3M: -8.1% YTD: +73.7% 1Y: +88.2% 3Y: +361.3% 5Y: +582.7%
$89.20
+16.22 (+22.23%)
After Hours: $89.50 (+0.30, +0.34%)
Weekly Expected Move ±4.7%
$70 $73 $77 $80 $84
NASDAQ · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 43 · $5.7B mcap · 75M float · 0.942% daily turnover · Short 48% of daily vol
Credit Risk of going bust: lower than 91% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down more than 99.9%), Kiniksa Pharmaceuticals International, plc would be worth roughly what it owes.
Total debt $8.9M against a stock market value of $5.69B.
Distance to default 14.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.4M (short-term plus half of long-term), stock volatility 47.9%; Altman Z'' 5.80. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$841M
Revenue
+58.9% YoY
$81M
Net Income
+1583.9% YoY
$183M
Free Cash Flow
+175.4% YoY
54.2%
Gross Margin
11.2%
Op. Margin
10.4%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE14.0%
ROA10.4%
ROIC51.6%

Valuation

P/E63.0
P/B10.8
EV/EBITDA43.0

Leverage

Debt/Equity0.01
Current Ratio3.90
Interest Cov.0.0x

Quality Scores

Piotroski F7/9
Altman Z14.59
Beneish M-3.03

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms